Europes largest scientific conference on rheumatic diseases.

Beneath the agreement with ProBioGen, AFFiRiS will measure the HuALN technology as a human being organoid model to investigate drug-related results in the context of the human immune system in order to select vaccine candidates suitable to be employed in humans. Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials. AFFiRiS with its cutting-edge technology in the vaccine field can be an ideal partner to help expand underline the strengths of ProBioGen’s HuALN technology. We are very much looking forward to this co-operation stated Michael Schlenk, CEO of ProBioGen. About AFFiRiS AG.. 4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011 4SC AG , a discovery and development company of targeted small molecule drugs for autoimmune and malignancy diseases, will present pre-clinical data on vidofludimus – its lead small-molecule drug applicant against autoimmune diseases – in systemic lupus erythematosus at EULAR 2011, Europe’s largest scientific conference on rheumatic diseases, in London, UK, from Might 25-28, 2011... A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants A.P. Pharma, Inc. , a specialty pharmaceutical organization, today announced that it has entered into definitive agreements with certain new and existing accredited traders providing for a private placement of common share and warrants where the Company can receive $24 million in gross proceeds. The normal share and warrants are being sold in models at a cost of $0.15 per unit. Each unit consists of one share of common stock and one warrant to purchase 0.5 extra shares of common stock at a cost of $0.18 per talk about. About July 1 The transaction is expected to close on or, 2011, subject to customary closing circumstances. We think that this financing will provide the resources essential to perform the activities needed to resubmit our New Drug Application for APF530 in the first fifty % of 2012 also to fund our procedures beyond the anticipated U.S.